Morphologic heterogeneity of acute promyelocytic leukemia: Therapy-related acute promyelocytic leukemia presenting with FAB-M2 morphology
โ Scribed by S. Sinha; L. Aish; T.H. Oo
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 285 KB
- Volume
- 81
- Category
- Article
- ISSN
- 0361-8609
No coin nor oath required. For personal study only.
โฆ Synopsis
To the Editor: Translocation t(9;22)(q34;q11) is found in 1-2% of newly diagnosed patients with de novo AML. The prognosis of Ph รพ AML is very poor with a median survival time of only 7 months. We present two patients with de novo Ph รพ AML who received induction chemotherapy and post-remission imatinib therapy.
A 73-year-old man was admitted in November 2003 with fatigue and palpitation. Physical examination showed only pallor. The Hb was 83 g/L, platelets 145 ร 10 9 /L, and WBC 1.4 ร 10 9 /L, 0.12 ร 10 9 /L blast cells. FACS analysis of marrow mononuclear cells showed 22% blast cells positive for HLA-DR, CD34, CD117, CD13, CD33, MPO, and CD38 and partially CD11b. Karyotype analysis of bone V V
๐ SIMILAR VOLUMES
Early diagnosis of t(15;17) acute promyelocytic leukemia (APL) is essential because of the associated disseminated intravascular coagulation and the unique response of the disease to all-trans retinoic acid (ATRA) therapy. Early diagnosis depends primarily on morphological recognition. The French-Am
A 22-year-old female presented with acute promyelocytic leukemia (APL). Treatment with all-trans retinoic acid (ATRA) resulted in a severe exacerbation of the coagulopathy 5 days after its introduction. This was complicated by bone marrow necrosis, parenchymal liver damage and acute tubular necrosis